This high variation has been attributed to several factors, such as tissue sample characteristics (SILs vs. invasive cancer), cancer stage (early vs. metastatic), history of chemotherapy treatment and combination antiretroviral therapy (cART)–treated patients exhibiting a lower prevalence of PD-L1 immunopositivity [18]. This evidence concerns the gene CD274 and cancer.